admin

MORRISTOWN, N.J., July 15, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for its Phase 2 Proof of Concept study of its lead product, recombinant human plasma gelsolin (rhu-pGSN) in hospitalized patients with severe COVID-19 pneumonia. BioAegis expects to recruit …

July 2020: BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment Read More »

MORRISTOWN, N.J., June 23, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical-stage private company focused on developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announces that its $5 million non-brokered bridge financing to accelerate its COVID-19 clinical trial was over-subscribed. Funding to Expedite Clinical Trial of COVID-19 TreatmentBioAegis …

June 2020: BioAegis Therapeutics Completes Over-Subscribed Financing for COVID-19 Trial Read More »

KYW Newsradio delves into why the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of the NIAID Strategic Plan for COVID-19 Research and what they hope to find. Dr. John Gallin, Chief Scientific Officer of the NIH Clinical Center and the NIH Associate Director for Clinical Research and Dr. Susan Levinson, …

June 2020: KYW InDepth Podcast – Why NIH is Studying a NJ Lab’s COVID-19 Treatment? Read More »

MORRISTOWN, N.J., May 21, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc. announces that the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of the NIAID Strategic Plan for COVID-19 Research. BioAegis’ lead product, recombinant human plasma gelsolin (rhu-pGSN), is based on this highly abundant circulating human protein. This study is a critical …

May, 2020: Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research Read More »

BioAegis says its ‘inflammation regulator’ is best weapon to fight COVID-19 Monday, May 11, 2020 | By Barbara Booth KEY POINTS: BioAegis Therapeutics believes that its lead product, recombinant human plasma gelsolin therapy (rhu-pGSN), is a viable therapeutic option for patients suffering from severe lung injury due to Covid-19. The private clinical stage company is …

May, 2020: BioAegis ‘Inflammation Regulator’ Highlighted in CNBC Feature Story on COVID-19 Read More »

MORRISTOWN, N.J., April 27, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc. has highlighted recently published gene expression data in animal studies where recombinant human plasma gelsolin (rhu-pGSN) significantly increased survival in pneumonia due to severe influenza.  Importantly, the gene expression analysis of lung tissue showed that gelsolin treatment downregulated genes associated with the over-exuberant production …

April, 2020: BioAegis Demonstrates Gelsolin Therapy Can Quell the Cytokine Storm and Promote Tissue Repair Read More »

MORRISTOWN, N.J., April 02, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc. is a clinical stage, private company focused on developing therapies for infectious, inflammatory, and degenerative diseases. Building upon intellectual property licensed from Harvard Medical School, BioAegis believes that its lead product, recombinant human plasma gelsolin therapy (rhu-pGSN), should be considered as a viable therapeutic …

April, 2020: Small NJ Biotech Firm, BioAegis Therapeutics, Accelerating Multiple Clinical Trial Submissions for Severe COVID-19 Pneumonia Patients Read More »

Our Chief Medical Officer and infectious disease expert, Dr. Mark DiNubile, was recently interviewed for a KYW InDepth podcast. Highlights of the podcast include:  What happens to our lungs when COVID-19 attacks our bodies and why some people end up in the ICU on ventilators. How the naturally-occurring human protein, plasma gelsolin, works in our …

March 2020: Chief Medical Officer Discusses COVID-19 in KYW InDepth Podcast Read More »